GS-441524

GS-441524 is an antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, which has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both tested against feline infectious peritonitis (FIP) in cell culture and found to be equivalent. Remdesivir was never tested in cats but GS-441524 has been found to be effective treatment for FIP, a lethal coronavirus disease which affects domestic cats and is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use.


GS-441524 is an antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, which has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both tested against feline infectious peritonitis (FIP) in cell culture and found to be equivalent. Remdesivir was never tested in cats but GS-441524 has been found to be effective treatment for FIP, a lethal coronavirus disease which affects domestic cats and is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use.
Read article on Wikipedia